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Abstract
Objective To study heterogeneity between patients with glyco-
gen storage disease type Ia (GSD Ia), a rare inherited disorder of
carbohydrate metabolism caused by the deficiency of glucose-6-
phosphatase (G6Pase).
Study design Descriptive retrospective study of longitudinal
clinical and biochemical data and long-term complications in
20 GSD Ia patients. We included 11 patients with homozy-
gousG6PCmutations and siblings from four families carrying
identical G6PC genotypes. To display subtle variations for
repeated triglyceride measurements with respect to time for
individual patients, CUSUM-analysis graphs were
constructed.
Results Patients with different homozygous G6PC mutations
showed important differences in height, BMI, and biochemi-
cal parameters (i.e., lactate, uric acid, triglyceride, and choles-
terol concentrations). Furthermore, CUSUM-analysis predicts
and displays subtle changes in longitudinal blood triglyceride
concentrations. Siblings in families also displayed important
differences in biochemical parameters (i.e., lactate, uric acid,
triglycerides, and cholesterol concentrations) and long-term
complications (i.e., liver adenomas, nephropathy, and
osteopenia/osteoporosis).
Conclusions Differences between GSD Ia patients reflect
large clinical and biochemical heterogeneity. Heterogeneity
between GSD Ia patients with homozygous G6PC mutations
indicate an important role of the G6PC genotype/mutations.
Differences between affected siblings suggest an additional
role (genetic and/or environmental) of modifying factors de-
fining the GSD Ia phenotype. CUSUM-analysis can facilitate
single-patient monitoring of metabolic control and future ap-
plication of this method may improve precision medicine for
patients both with GSD and remaining inherited metabolic
diseases.
Keywords CUSUM . ESGSDI . GSD Ia .G6PC .
Heterogeneity .Modifying factors
Introduction
Glycogen storage disease type Ia (GSD Ia; OMIM #232200)
is a rare inherited disorder of carbohydrate metabolism caused
by mutations in the G6PC gene, resulting in deficiency of
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glucose-6-phosphatase (G6Pase). The subsequently impaired
hydrolysis of glucose-6-phosphate (G6P) to glucose and phos-
phate affects the final common pathway of glycogenolysis and
gluconeogenesis (Bali et al n.d.; Froissart et al 2011).
Symptoms and signs include severe fasting intolerance, failure
to thrive, and hepatomegaly. Biochemically, the phenotype is
characterized by non-ketotic hypoglycemia, hyperlactidemia,
hyperuricaemia, and hyperlipidaemia (Bali et al n.d.). Dietary
management has greatly improved the life expectancy of GSD
Ia patients, changing from an acute, fatal disease into a chronic
disorder. Despite intensive dietary management, important
long-term complications include the liver (hepatocellular ad-
enomas and carcinomas), kidneys (proteinuria, renal insuffi-
ciency, stones), and bone (osteopenia, osteoporosis) (Bali et al
n.d.; Rake et al 2002a, b).
Cross-sectional studies such as the European Study on
Glycogen Storage Disease Type 1 (ESGSDI) focused on the
complete cohort of GSD Ia patients, but longitudinal data on
clinical heterogeneity between individual GSD Ia patients
have been poorly documented. In contrast with the classical
childhood GSD Ia phenotype, case reports illustrate patients
with milder phenotypes, clinically presenting during late
childhood with non-symptomatic hepatomegaly or adulthood
with gouty arthritis and benign/malignant hepatic tumors
(Takahashi et al 2000; Shieh et al 2011; Cassiman et al
2010; Nakamura et al 2001; Matern et al 2002; Keller et al
1998). Although these patients have not experienced clinically
relevant fasting intolerance, their abnormal biochemical pro-
files resemble classical GSD Ia patients. In addition, observa-
tions in two siblings suggest that clinical heterogeneity cannot
be solely explained by theG6PC genotype (Rake et al 2000a).
Furthermore, data analysis has focused largely on traditional
methods describing differences between groups by expressing
means or medians. However, patient care for metabolic pa-
tients often is characterized by repeated clinical and biochem-
ical measurements and their analysis can be complemented by
inter-individual analysis methods, such as Cumulative Sum
analysis (CUSUM-analysis).
This is a retrospective study of longitudinal clinical and
biochemical parameters from (1) GSD Ia patients with homo-
zygosity for different G6PCmutations and (2) patients within
GSD Ia families carrying identical G6PC genotypes.
Patients and methods
Patients The Medical Ethical Committee of the University
Medical Center Groningen approved the study protocol
(MEC 2014|342). Data were studied from GSD Ia patients
followed by two centers. Patients were selected based on
G6PC genotypes/mutations and the availability of sufficient
data. For all GSD Ia patients in this study the diagnosis was
genetically confirmed and displayed according to the refer-
ence sequence NM_000151.3.
Clinical and biochemical data Longitudinal data on clinical
and laboratory data and long-term complications were re-
trieved from the paper and electronic files before 01–02-2016.
Clinical parameters included height, weight, weight for
height, BMI, and data of the prescribed diets. Height and
BMI were recorded at last check-up and compared with
Dutch standard growth diagrams (LUMC-TNO 1997 in cases
A, B, and C and families I-III; LUMC-TNO 2010 in case D).
For the patients from the University of Florida, biometric data
were compared to the standard growth diagrams from the
CDC 2000. Target height range was determined accordingly
for all patients.
Biochemical parameters included blood concentrations that
are closely related to metabolic control (i.e., lactate, uric acid,
triglycerides (TG), and cholesterol) and urine parameters (i.e.,
creatinine, albumin and total protein) as mentioned in the pub-
lished guidelines(Rake et al 2002a; Kishnani et al 2014).
Long-term complications were recorded at the last check-
up. Liver adenoma(s) was defined as one or more focal lesions
detected by standard imaging techniques. Nephropathy was
defined as micro albuminuria (either 30–300 mg/24 h, or if
previous data was not available albumin/creatinine >3.5 and
>2.5 for females and males, respectively) and/or proteinuria
(protein/creatinine >45 mg/mmol). Bone mineral density was
evaluated by duel-energyX-ray absorptiometry scan (DEXA).
Osteopenia was defined as bone mineral density T-scores be-
tween −1.0 and −2.5 SDs determined at one site. Osteoporosis
was defined as bone mineral density T-scores of −2.5 SDs or
lower determined at one site. The values are compared to the
ideal or peak bone mineral density of healthy 30-year old
adults.
Statistical analysis Statistical analysis was performed using
Microsoft® Excel for Mac Version 15.19.1 and Graphpad
Prism version 5.03 for Windows (San Diego, CA, USA,
(www.graphpad.com)). Differences between groups were
studied using either Mann-Whitney U test (in families I, II
and IV) or Kruskal-Wallis test followed by Dunn’s multiple
comparison (in patients with homozygous G6PC mutations
and family III). Differences were considered statistically sig-
nificant at p < 0.05.
To display subtle variations for repeated measurements with
respect to time for individual patients, CUSUM-analysis graphs
were constructed. CUSUM-analysis is a method in which each
measurement is seen as a deviation from the mean value of the
parameter over time. The cumulative effect of the deviations of
each measurement to the mean is made visible as CUSUM-
analysis graphs. However, in our retrospective analysis, interpre-
tation of CUSUM-analysis was complicated because time inter-
vals between TGmeasurements were not constant, which means
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that periods of high measurement density would have a dispro-
portional effect in the CUSUM-analysis. To correct for different
time intervals, the TG values were interpolated to equidistant
time intervals (t = 0.01 year, approximately 3.65 days). This
interpolation interval was chosen to make the calculation of the
CUSUM easier. After calculating average blood TG concentra-
tions (TGmean), for each value ΔTG was calculated as TGn-
TGmean. At the first time point CUSUM equals ΔTG. For serial
measurements at time point n, CUSUM is calculated as ΔTG +
CUSUMn-1.
Results
Twenty GSD Ia patients were included from 14 families, 12
males and eight females. Median age was 21.5 years (range
4.2–43.0).
Differences between GSD Ia patients with homozygosity
for different G6PC mutations
Parameters of 11 patients with homozygosity for different
G6PC mutations are presented in Table 1 (UMCG; patients
A-D) and Table 2 (UF; patients E-K). Figure 1 presents (1)
longitudinal data of blood TG concentrations and the first
order derivative of blood TG concentrations with respect to
time and (2) CUSUM-analysis for patients A-D.
Patient A presented clinically with severe hypoglycemia’s in
the first days of life, when plasma TG concentrations were
0.22 mmol/L. Enzymatic studies had confirmed diagnosis of
GSD Ia, but no molecular studies had been performed at that
time. She had been referred to the UMCG at the age of 16.
Despite strict dietary management, height has remained below
target range and she underwent a partial hepatectomy at the age
of 19 years due to liver adenomas of which the largest was
5.9 cm (arrow 1 Fig. 1a). The patient was one of the very few
GSD Ia patients known in the UMCG who was not growing
within her target range. However, dietary compliance had been
questioned over the years. In an attempt to improve hermetabolic
control before surgery, she was hospitalized 3 days before the
procedure. Blood lactate concentrations only decreased to
2.3 mmol/L after increasing both enteral and parenteral carbohy-
drate intakes to supra-physiological values (4.7 and 3.9 mg/kg/
min, respectively). Based on these observations, after the hospi-
talization the prescribed absolute dietary carbohydrate intake was
increased to 5 mg/kg/min glucose, 2.2 times the estimated en-
dogenous glucose production rate, according to literature
(Huidekoper et al 2014). Following this intervention, blood lac-
tate concentrations remained increased despite higher carbohy-
drate intake (ranging between 2.9 to 7.1 mmol/L). TG concen-
trations (absolute and CUSUM) decreased subsequentually,
reflecting improved metabolic control, but she gained 8 kg of
body weight, reflecting the delicate balance between under- and
over-treatment. At that time, results on molecular testing became
available and confirmed homozygosity for the c.79delC/
p.Gln27Argfs*9 mutation in exon 1 of the G6PC gene, leading
to a severely truncated protein without any of the essential do-
mains necessary for the G6Pase activity (Angaroni et al 2004).
Patient B is the daughter of Turkish immigrants growing in/
above the target range, (not even) adjusted for her ethnicity.
She developed severe iron treatment resistant anemia due to
multiple liver adenomas, for which she underwent a liver
transplantation at the age of 19 years (arrow 1 in Fig. 1b). In
the CUSUM-analysis, this is visible as a rapid decrease of the
CUSUM, corresponding to the TG mean. This represents im-
proved metabolic control.
The family history of patient C (family III) will be summa-
rized in the following section. After the moment this patient,
first believed to have GSD IX, received the correct diagnosis
of GSD Ia (arrow 1 in Fig. 1c), dietary management and the
compliance with this dietary management improved. TG
values (absolute and CUSUM) subsequently normalized. In
the CUSUM-analysis, this is visualized since the CUSUM
decreased to 0 mmol/L, corresponding to the TG mean.
Patient D presented clinically during a gastro-enteritis at
the age of 22 months with failure to thrive and hepatomegaly.
After introduction of dietary management, biometrical data,
liver size, and biochemical parameters of metabolic control
have been outstanding. In the CUSUM-analysis, it can be seen
that the CUSUM is relatively low compared to patients A, B,
and C, with a maximum of 146mmol/L depicted at the right y-
axis. She is currently still on continuous nocturnal gastric drip
feeding with a daily carbohydrate intake of 3.7 mg/kg/min
(1.2 times the estimated endogenous glucose production)
(Huidekoper et al 2014).
Differences between patients within GSD Ia families
carrying identical G6PC genotypes
Table 3 presents the clinical and biochemical parameters and
long-term complications between siblings in four GSD Ia fam-
ilies. Heterogeneity between these GSD Ia patients is illustrat-
ed by significant differences in clinical parameters (i.e., height
ranges from −2.7 to +1.9 SDS), biochemical parameters (i.e.,
TGmedian ranges from 2.6 to 38.8 mmol/L), and development
of long-term complications in every family.
In family I, patient 1 was additionally diagnosed with lipo-
protein lipase deficiency, but his brother was not. Patient 1
additionally developed liver adenomas and nephropathy, in
contrast to his brother.
Family II was reported previously (Rake et al 2000b). The
patients differ with respect to lactate, TG and uric acid con-
centrations. Both patients developed liver adenomas, but only
patient 4 developed osteoporosis.
Family III represents four affected male GSD Ia patients,
including patient C. The patients have been considered GSD
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type IX patients for most of their lives because of their family
history suggesting X-linked inheritance and their relatively
mild fasting intolerances. The latter was reflected by the fact
that patient 6 from family III was the index patient with an
older affected brother diagnosed after him. The brothers were
initially prescribed relatively low doses of uncooked corn-
starch (UCCS) during the day, and late evening meals.
Surprisingly, after next generation sequencing analysis
Table 1 Clinical and biochemical parameters in four GSD Ia patients with homozygosity for one G6PC mutation, who are followed in the UMCG
Case A B C D
G6PC mutation
cDNA c.79delC c.247C > T c.467G > T c.1039 C > T
protein p.Gln27Argfs*9 p.Arg83Cys p.Trp156Leu p.Gln347X
Descent Caucasian Turkish Caucasian Caucasian
Gender Female Female Male Female
Year of birth 1994 1994 1992 2003
Age at clinical presentation
(months)
0 2 0 22
Largest height
(cm) 150 172 176 151
(SDS) −3.3^ +0.3 −1.2 −0.4
BMI
(kg/m2) 26.6 27.7 19.7 17.2
(SDS) +1.6 +2.0 −0.9 −0.1
Lactate (mmol/L) 5.8c,d (2.3–10.6) 4.3c,d (0.9–18.6) 2.7a,b (0.8–5.5) 1.4a,b (1.0–1.4)
Uric acid (mmol/L) 0.28 (0.12–0.46) 0.29 (0.16–0.58) 0.26 (0.16–0.38) 0.28 (0.25–0.33)
Triglycerides (mmol/L) 12.5 (0.2–24.4) 6.1 (0.6–14.1) 4.2 (2.1–8.6) 2.2 (1.1–4.1)
Cholesterol (mmol/L) 10.3 (6.8–14.5) 5.0 (3.2–6.3) 5.9 (3.3–7.6) 3.6 (2.5–5.1)
Liver adenoma(s) Yes Yes No No
Nephropathy No No No No
Bone disease
Osteoporosis LS LS,PF,R LS No
Osteopenia No No No LS, PF, R
Legend: Biochemical parameters are presented as median and range. Patient C corresponds with patient III.7 in Table 3. a , significantly different
compared to case A, b , significantly different to case B, etc.; ^, height outside of target range; LS, lumbar spine; NR, not recorded; PF, proximal femur; R,
radius. Differences were considered statistically significant at p < 0.05
Table 2 Clinical and biochemical parameters in seven GSD Ia patients with homozygosity for one G6PC mutation, who are followed in the GSD
program, University of Florida
Case E F G H I J K
G6PC mutation
cDNA c.247C > T c.79delC c.379_380
dupTA
c.467G > T c.79C > T c.379_380
dupTA
c.323C > T
protein p.R83C p.Gln27Argfs*9 p.Y128Tfs p.W156 L p.Q27X p.Y128Tfs p.T108I
Descent Caucasian Caucasian Hispanic Caucasian Indian Hispanic Lebanese
Gender Female Male Female Male Female Male Female
Year of birth 1983 1994 2011 2002 2000 2007 1997
Age at clinical presentation (months) 5 2 0 91 0 0 12
Last measured height
(cm) 152.4 178.6 93.1 144.0 140.0 126.4 158.3
(SDS) −1.7^ 0.2 0.0 −0.6 −1.1 −1.0 −0.8
BMI
(kg/m2) 25.1 25.6 17.4 20.5 21.2 20.2 40.2
(SDS) NR NR NR NR NR NR NR
Lactate (mmol/L) 4.1f,g,h,i,j,k
(0.5–10.9)
1.9e,h,i,j (0.7–4.8) 1.6e (1.4–1.9) 1.2e,f,j (0.6–3.2) 1.3e,f (0.9–4.5) 1.5e,h (0.7–5.1) 1.6e,f (0.3–3.3)
Uric acid (mmol/L) 0.37k (0.21–0.58) 0.44i (0.32–0.55) 0.32k (0.24–0.39) 0.40k (0.29–0.50) 0.28f,k (0.21–0.37) 0.29k (0.25–0.58) 0.52e,g,h,i,j
(0.42–0.65)
Triglycerides (mmol/L) 8.7 (0.8–17.7) 7.5 (4.8–9.3) 3.6 (1.8–8.2) 1.4 (0.6–2.1) 4.3 (1.2–15.2) 1.2 (0.8–13.0) 2.3 (1.0–5.6)
Cholesterol (mmol/L) 5.98 (4.7–8.6) 5.98 (2.9–7.7) 5.00 (3.9–5.4) 4.64 (3.2–5.7) 3.73 (3.0–5.8) 3.50 (2.8–6.6) 6.37 (4.8–9.1)
Liver adenoma(s) Yes Yes No No No Yes Yes
Nephropathy Yes No No No No No No
Bone disease
Osteopenia No NR NR NR NR NR NR
Osteoporosis LS, PF NR NR NR NR NR NR
Legend: Biochemical parameters are presented asmedian and range. Legend: e , significantly different compared to case E, etc.; ^, height outside of target
range; LS, lumbar spine; NR, not recorded; PF, proximal femur; R, radius. Differences were considered statistically significant at p < 0.05
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became available, it demonstrated homozygosity for the
c.467G > T/p.Trp156Leu G6PC mutation in exon 4, known
to be associated with retained residual G6Pase activity (Shieh
et al 2001; Kirk et al 2013). After revision of the diagnosis,
they were prescribed late-evening doses of extended release
cornstarch, aiming at normalization of laboratory parameters,
although dietary compliance had been limited. There were no
significant differences in clinical or biochemical parameters
between the family members. However, patient 5 was the only
sibling that developed three liver adenomas. These have not
increased in size in the subsequent 2 years.
In family IV, the siblings are identical twins. Their clinical
and biochemical parameters do not differ significantly and
patients 9 and 10 both developed liver adenomas. However,
in contrast with this brother, at the age of 17, the liver adeno-
mas in patient 10 developed so rapidly that liver transplanta-
tion was deemed necessary. At this age, this patient also de-
veloped nephropathy.
Discussion
This is the first report of large heterogeneity between GSD Ia
patients based on retrospective study of longitudinal clinical
and laboratory data. This report shows that there are differ-
ences GSD Ia patients with homozygosity for different G6PC
mutations and differences between patients within GSD Ia
families carrying identical G6PC genotypes.
Based on the genotype of the patients in this study, one can
speculate on the cause for the heterogeneity. In this study,
patients with homozygosity for either severe nonsense muta-
tions or active site G6PC mutations appear to be more
severely affected clinically (i.e., patient A, B, E, and F in
Tables 1 and 2). Historically, GSD Ia diagnosis required the
confirmation of impaired G6Pase enzyme activity in frozen
liver tissue. Nowadays genetic testing (including G6PC gene
sequencing) is the preferred method since it is less invasive.
Based on in vitro studies, many G6PC mutations can be cat-
egorized according to their predicted catalytic, helical, or non-
helical locations in the enzyme (Shieh et al 2001; Chou and
Mansfield 2008; Bruni et al 1999). Genotype-phenotype cor-
relations have not been studied systematically and are com-
plex because by far most GSD Ia patients are compound het-
erozygous for different G6PCmutations (Bali et al n.d.; Rake
et al 2002b; Wang et al 2011).
Furthermore, the differences between affected siblings with
identicalG6PCmutations suggest a contribution of additional
(genetic and/or environmental) modifying factors that theoret-
ically modify the GSD Ia phenotype.
Variations of residual endogenous glucose production may
be a modifying factor in GSD Ia patients. In healthy subjects,
endogenous glucose production rate is age dependent and de-
creases relatively with body weight and age (Huidekoper et al
2014; Bier et al 1977). Interestingly, in GSD Ia patients, whole
body in vivo endogenous glucose production may reach
∼60% of normal, despite severely reduced or absent in vitro
hepatic G6Pase activity (Huidekoper et al 2014; Kalhan et al
1982; Tsalikian et al 1984; Schwenk and Haymond 1986;
Roden et al 2007). The origin of this glucose production is
still a matter of debate. The metabolic block may be compen-
sated for by (combinations of) residual G6Pase activity,
(muscle) glucose-6-phosphatase-β, and/or alternative glyco-
genolysis (by the α-glucosidase or debranching pathway).
Besides the product (i.e., glucose) deficiency, there is substrate
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(i.e., G6P) accumulation in the endoplasmic reticulum of GSD
Ia patients (Bali et al n.d.; Froissart et al 2011). G6P accumu-
lation affects transcription and enzyme activity (including car-
bohydrate response element binding protein and 11β-
hydroxysteroid dehydrogenase) of several metabolic path-
ways such as glycolysis, de novo lipogenesis, and the pentose
phosphate pathway, which together create the complex clini-
cal and biochemical GSD Ia phenotype (Oosterveer and
Schoonjans 2014; Melis et al 2015).
This study introduces CUSUM-analysis to visualize subtle
time-dependent variations of retrospectively collected TG-
concentrations in cases A-D. However, it needs to be men-
tioned that CUSUM-analysis of retrospectively collected TG
concentrations has been complex, because time intervals be-
tween measurements were not constant. Moreover, the varia-
tions in plasma TG concentrations in GSD Ia patients are not
as fast as changes in glucose concentrations in these patients.
Therefore, we hypothesize that prospective application of
CUSUM-analysis may be a powerful tool to identify early
and critical biochemical variations in patients with inherited
metabolic diseases. The correlation between CUSUM-
analysis of relevant biomarkers and clinically relevant out-
come parameters deserves future prospective study.
There is no clear definition of ‘good metabolic control’ for
GSD Ia patients, although several biomedical targets (includ-
ing growth, liver size, and standard laboratory parameters
such lactate, TG, cholesterol, and uric acid levels) are men-
tioned in GSD I management guidelines (Rake et al 2002a;
Kishnani et al 2014). TG concentrations are considered as an
important biometrical parameter of metabolic control.
ESGSDI has recommended to aim at TG < 6.0 mmol/L
(Rake et al 2002a, b). Significant differences in adenoma
development/progression have been reported between GSD
Ia patients with 5-year mean TG concentrations <500 mg/dL
(i.e., 5.7 mmol/L) and >500 mg/dL (Wang et al 2011). In the
above mentioned reports, GSD Ia patients were considered a
homogenous group (Rake et al 2002a; Kishnani et al 2014).
This study emphasizes that dietary management of GSD Ia
patients requires individualized approaches.
Conclusion
We report large heterogeneity of (long-term) clinical and bio-
chemical parameters between GSD Ia patients. Differences
between patients carrying homozygousG6PCmutations indi-
cate that the G6PC genotype is an important determinant of
the phenotype. Differences between affected siblings with
identicalG6PC mutations suggest a contribution of additional
(genetic and/or environmental) modifying factors to GSD Ia
symptoms and signs. CUSUM analysis can be helpful to iden-
tify early changes in metabolic control for individual patients,
which opens up possibilities to move toward precision medi-
cine for metabolic patients.
BMI, body mass index; CGM, continuous glucose moni-
toring; CUSUM, cumulative sum; ESGSDI, European Study
on Glycogen Storage Disease Type I; G6P, glucose-6-
phosphate; G6Pase, glucose-6-phosphatase; G6PC, glucose-
6-phosphatase, catalytic subunit; LS, lumbar spine; PF, prox-
imal femur; R, radius; TG, triglycerides; UCCS, uncooked
cornstarch.
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